https://www.selleckchem.com/sc....reening/kinase-inhib
reatment) of 8.3±2.6 and 4.4±1.8 months, respectively. CONCLUSION Overall survival was shown to be shorter in this real world study compared with randomized clinical trials, and underlines the differences in clinical outcomes of patients in a real life setting. This baseline real world study has demonstrated poor survival outcomes in this patient group prior to availability of poly-ADP ribose polymerase inhibitors. © IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.OBJECTIVE The CI
Like
Comment
Share
